AbbVie Acquires Apogee for $10.9 Billion, Boosts Immunology

announced an agreement to acquire inflammatory and immunological drug maker Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, a move that sent Apogee shares surging 47 percent and AbbVie shares up 4 percent. The transaction is expected to close in the third quarter of 2026, subject to customary conditions, and is projected to be accretive to AbbVie's adjusted earnings per share starting in 2032.

This acquisition significantly expands AbbVie's existing immunology portfolio and accelerates its clinical presence in the respiratory space. Apogee's pipeline includes multiple clinical-stage candidates for atopic dermatitis and asthma, notably zumilokibart (APG777) and APG273.

According to AbbVie, these assets hold "mega-blockbuster peak sales potential." Robert Michael, chairman and chief executive officer of AbbVie, stated the deal adds "highly differentiated clinical-stage assets" and positions AbbVie to transform inflammatory disease care. Fairmount Funds Management LLC and Venrock Associates have entered voting agreements in support of the transaction.